Somatostatin receptor type 1 (SSTR1) (SSTR1)

Somatostatin receptor type 1 (SSTR1) is a member of the G protein-coupled receptor family that mediates the inhibitory effects of the peptide hormone somatostatin [1, 2]. It is widely expressed in the brain, pancreas, gastrointestinal tract, and various endocrine glands, where it plays a critical role in regulating neurotransmission and inhibiting the release of hormones such as growth hormone and prolactin [3, 7, 8]. SSTR1 is distinguished from other somatostatin receptor subtypes by its unique ability to inhibit Na+/H+ exchange activity through both pertussis toxin-sensitive and -insensitive pathways [3, 12]. In the context of disease, SSTR1 is often overexpressed in neuroendocrine tumors, prostate cancer, and pituitary adenomas, contributing to the regulation of tumor cell growth and secretory activity [7, 13, 15]. While first-generation somatostatin analogs like octreotide have low affinity for SSTR1, newer multi-receptor agonists such as pasireotide and experimental selective agonists like BIM-23926 are utilized or studied for their therapeutic potential in managing hormone-related disorders and malignancies [9, 13, 18]. Additionally, SSTR1 has been implicated in the modulation of immune responses and is expressed in conditions such as Graves' disease [7, 17]. The receptor's signaling also involves the modulation of mitogen-activated protein kinase (MAPK) pathways, further influencing its anti-proliferative effects [3, 13].

Other names

Somatostatin receptor 1sst1SS1RSRIF-1Somatostatin receptor subtype 1

SSTR1 acts as a G protein-coupled receptor that, upon activation by somatostatin or its analogs, couples to inhibitory G proteins (Gi/Go) to inhibit adenylyl cyclase activity, thereby reducing intracellular cAMP levels [2, 3, 8]. It also uniquely mediates the inhibition of Na+/H+ exchange activity and modulates potassium and calcium channels, leading to the suppression of hormone secretion and the inhibition of cell proliferation and migration [1, 12, 13].